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A B S T R A C T
Hemophagocytic syndrome (HPS) is a rare condition characterized by overactive histiocytes, hepatosplenomegaly, fe-
ver and cytopenia, with two major types: familial, autosomal recessive genetic disease and acquired that can occur dur-
ing systemic infections, immunodeficiency or malignancy. Inappropriate activation of macrophages by cytokines is the
major mechanism of the disease. We report a case of an adult patient with HPS. After thorough clinical investigation, we
have not been able to establish the underlying disease, and corticosteroids therapy was initiated empirically. After 8
months follow-up the patient is well with normal laboratory findings.
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Introduction
Hemophagocytic syndrome (HPS), also known as he-
mophagocytic lymphohistiocytosis (HLH) or erythropha-
gocytic lymphohistiocytosis (EL) is a rare condition char-
acterized by overactive (otherwise normal) histiocytes,
hepatosplenomegaly, fever and cytopenia1.
There are two major types of HPS2. Primary (i.e. fa-
milial – FHL) is the inherited form, autosomal recessive
genetic disease with onset in the first year of childhood.
Secondary (i.e. acquired HPS) occurs after strong immu-
nologic stimulation that can be a part of systemic infec-
tions, autoimmune diseases, immunodeficiency or malig-
nancy.
Accepted theory for pathophysiology involves inap-
propriate activation of macrophages by activated T cells3.
Large quantities of cytokines, primarily tumor necrosis
factor- (TNF-), interferon gamma (INF-8) and granu-
locyte-macrophage colony-stimulating factor (GM-CSF)
cause macrophage proliferation and activation with fur-
ther release of interleukin-1 (IL-1) and IL-64. Interleu-
kin-18 seems to have an important role in the activation
also5. Activated macrophages phagocytose blood cells
throughout reticuloendothelial system which is the main
site of involvement.
The triggering mechanisms that lead to inappropriate
immune activation are different in familial and acquired
HPS. Perforin, a membrane protein of cytotoxic cells
such as NK cells has an important role in the genesis of
at least one type of FLH6,7. It is a part of cytoplasm gran-
ules of NK cells and cytotoxic T-cells that are released
after stimulation to form pores in target cells thus dam-
aging and ultimately destroying it by osmotic lysis. Pa-
tients with perforin deficiency have impaired NK activity
that could lead to activation of T-cells in an inappropriate
manner. Other NK cell disorders have been associated
with FLH8. Secondary HPS can be initiated by a number
of pathogens, of which the best understood is the patho-
genesis of Epstein-Barr virus (EBV) associated HPS9,10.
Any kind of tumor, but more frequently lymphomas can
lead to production of cytokines whether by direct produc-
tion or immune system stimulation. Overproduction of
TNF-, INF-8 and other cytokines can lead to the cascade
of reaction leading to macrophage over-stimulation.
Clinical presentation always includes fever, cytopenia
and splenomegaly. Skin rash, hepatomegaly, lymphade-
nopathy, CNS disorders, jaundice and coagulopathy may
also be present. Laboratory findings in addition to cyto-
penia include hyperfibrinogenemia, hypertriglyceride-
mia, high ferritine and low haptoglobine concentrations,
liver damage and hyponatremia. Characteristic finding is
cytological or histological confirmation of hemophago-
cytosis in an aspirate or biopsy of bone marrow, liver,
spleen, lymph node or skin. Diagnostic criteria for HPS
have been established1,2. NK cell activity can be deter-
mined as an aid in determining between HPS types, since
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reactive disease has normal NK activity, unlike familial
FLH. NK cell is also impaired in secondary HPS espe-
cially in systemic onset as juvenile rheumatoid arthritis.
Perforin expression can also be determined, as well as
PRF-1 gene mutations and other gene mutations.
Familial types of HPS are treated with different ap-
proaches that include corticosteroids, immunosuppres-
sive and antineoplastic drugs11. The main goal is to
achieve clinical stability. In cases of disease refractory to
such treatment, bone marrow transplantation (BMT)
should be considered12. In the case of reactive HPS, un-
derlying disease must be sought and treated appropri-
ately if present. The same treatment as for FHL can be
applied and for non-reactive patients a BMT must be
considered.
Case Report
A 59-year-old male was admitted because of a fever
that lasted for 6 weeks, anemia, leucopenia and weight
loss of 8 kg over several months. Fever occurred usually
in the afternoons, without chills and there were no other
symptoms.
Patient’s history was scarce: he had suffered a brain-
stem infarction 4 years before, and had his gallbladder
removed due to gallstones. Initial examination revealed
fever (37.8 °C), pale skin, hepatomegaly and splenome-
galy (4 cm and 5 cm below costal margin respectively).
Blood count showed neutropenia and anemia, whereas
thrombocytes were only slightly reduced. Hyponatremia,
hypertriglyceridemia, elevated liver enzymes and lactate
dehydrogenase activity, elevated ferritine and low hapto-
globine concentrations were present. Other electrolytes
were normal, no alterations in coagulation tests were
present and electrophoresis of serum proteins was nor-
mal as well as the values for available tumor markers
(PSA, CEA, AFP, Ca-19-9, Ca-125).
Imaging methods (chest radiogram, abdominal ultra-
sound and CT) revealed no pathology in the thorax, en-
larged spleen and liver with homogenous structure and
several enlarged retroperitoneal lymph nodes.
Clinical presentation and laboratory findings were
suggestive for hematological or infectious disease, but
numerous microbiological tests performed during the
course of hospitalization were negative. Several blood
and urine cultures, also pharyngeal and nasal swabs
were taken and all were negative. Serology for B and C
hepatitis viruses and HIV virus was negative. IgG anti-
bodies for Cytomegalo and Epstein-Barr virus were posi-
tive, but IgM were negative. Available tests for leischa-
miasis, shistosomiasis and malaria were negative.
Cytology of sternal aspirate was done early, and sho-
wed normal hematopoesis, but histiocytes that phago-
cyte mostly erythrocytes and rarely granulocytes were
present, as well as some multinuclear cells. Following
that finding, spleen biopsy and bone barrow biopsy and
were done and phagocytosis of erythrocytes was found in
both. The diagnosis of hemophagocytic syndrome was set.
In the following patient evaluation possible causes for
secondary HPS were considered. No proof for malignant
disease was found after examination of gastrointestinal,
respiratory and urinary systems. No criteria for systemic
autoimmune disease were met. Besides the positive anti-
EBV and anti-CMV IgG, no infection could have been
connected with the patient’s condition.
Without any known condition that could have been
treated, corticosteroid treatment was chosen. A daily
dose of 40 mg (0.5 mg per kg) methylprednisolone was
administered orally and clinical condition improved rap-
idly. Fever disappeared three days after initiating treat-
ment and blood count normalized on 7th day of treat-
ment, patient was discharged three days after that. The
dose of methylprednisolone was reduced gradually over
eight weeks to 12 mg per day, but that led to a fall in
blood count, primarily thrombocytes (110,000/ml) and
leucocytes (3,000/mL). The values normalized with in-
crease of steroid dose. During the eight-month follow up,
our patient developed steroid diabetes, but other labora-
tory findings remained normal even after another reduc-
tion of drug dose to 16 mg daily, with well general condi-
tion of the patient. Repeated abdominal ultrasounds
showed gradual reduction of spleen size which normal-
ized six months after initiation of treatment.
Discussion
In the presented case of an adult male patient with
HPS, no underlying condition that could be »accused« for
the condition could be proven. Malignant disease, bacte-
rial and parasitic infection, as well as autoimmune or
other immunology disorder has been ruled out. The pa-
tient was serologically positive for a past EBV and CMV
infection (positive IgG and negative IgM). Clinical course
of the disease is not in concordance with known course of
EBV associated HPS which is mainly much more severe.
Any infection in theory could trigger the disease, and
since there has been at least six weeks from the onset of
symptoms to first examination, it is possible that an un-
known infectious agent other than CMV or EBV was in-
volved. No actual infection however was present during
the hospitalization.
HPS is usually described as severe even in the case of
secondary type. We have managed to achieve complete
remission after several weeks of low dose corticosteroids
treatment, but maintenance therapy is still required for
our patient.
Although clinical presentation of the condition is any-
thing but characteristic, and laboratory findings are also
not specific, histology or cytology finding of hemophago-
cytosis is very characteristic, and necessary for the diag-
nosis. In cases of unexplained fever with hepato and
splenomegaly it should be considered, especially if the
laboratory findings are suggestive. There are reports
that up to 60% of initial bone marrow aspirates can be
negative for hemophagocytosis, so the examination should
be repeated at least once if there is clinical suspicion of
HPS.
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HEMOFAGOCITARNI SINDROM – TREBAMO LI ^E[]E MISLITI NA NJEGA?
S A @ E T A K
Hemofagocitarni sindrom (HFS) je rijetko stanje karakterizirano hiperaktivno{}u histiocita, hepatosplenomegali-
jom, vru}icom i citopenijom. Postoje dva osnovna oblika sindroma: familijarni, autosomno recesivna nasljedna bolest te
ste~eni oblik koji mo`e nastati za vrijeme sistemskih infekcija, imunodeficijencije ili uz maligne bolesti. Neodgovaraju}a
aktivacija makrofaga citokinima osnovna je u mehanizmu nastanka ove bolesti. Opisujemo odraslog bolesnika s HFS
kod kojega nakon temeljite klini~ke obrade nije otkriven primarni uzrok bolesti, a sistemska terapija kortikosteroidima
emprijski uklju~ena. Nakon osam mjeseci kontrole bolesnik je klini~ki dobro s urednim laboratorijskim nalazima.
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